Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus

Chou Chien-Wen; Ou Horng-Yih; Hsiao Shu-Hwa; Wu Ta-Jen

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus

Author(s):

Chou Chien-Wen¹,

Ou Horng-Yih²,

Hsiao Shu-Hwa²,

Wu Ta-Jen³

1Division of Endocrinology and Metabolism, Chi-Mei Medical Center, Tainan

2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan

3College of Medicine, National Cheng Kung University, *, Taiwan

International Journal of Endocrinology and Metabolism:Vol. 4, issue 2; 63-69

Article type:Research Article

Received:Apr 17, 2005

Accepted:Dec 09, 2005

How to Cite:Chou Chien-WenOu Horng-YihHsiao Shu-HwaWu Ta-JenDifferential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus.Int J Endocrinol Metab.4(2):63-69.

Abstract

To investigate the responses in terms of body weight, glycemic control, metabolic control, and the side effects to acarbose add-on therapy in obese and non-obese type 2 diabetes patients with inadequately controlled by sulfonylureas and metformin. Materials and Methods: Forty obese (BMI≤ 27) and 80 sex- and age-matched non-obese patients with type 2 diabetes mellitus were enrolled in this 3-month, open-label, case-controlled trial for acarbose add-on therapy. Totally 111 (73 non-obese and 38 obese) patients completed 3-month acarbose add-on therapy. This study adopted a 2-center open-label parallel group design. After a 4-week run-in period, acarbose was added (ti-trated up to 100 mg t.i.d.) to the current sulfony-lureas and metformin combined therapy of sub-jects. Both obese patients (9.3±1.3% vs. 8.3±1.6%, p<0.0001) and non-obese patients (9.4±1.2% vs. 8.4±1.2%, p<0.0001) showed decreased HbA1c af-ter therapy. While obese patients showed a sig-nificant serum alanine aminotransferase (ALT) (61±26 vs. 49±18, p<0.0001) and triglyceride re-duction (242±127 vs. 187±71, p<0.01) after add-on therapy, non-obese patients did not. Neither obese (74.8±9.2 vs. 74.4±9.8 kg, N.S.) nor non-obese patients (61.9±7.9 vs. 61.6±7.7 kg, p=0.0579) show significant decrease in body weight. Conclusion: Both obese patients and non-obese patients showed decreased HbA1c after acarbose therapy. Obese patients had an additional bene-fit of a decrease in their previoulsly elevated ALT and triglyceride levels after acarbose ther-apy.

Keywords

Type 2 diabetes mellitus

Acarbose

Obesity

Full Text

Full text is available in PDF

comments